Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2009: Volume 14/ Issue 18 Article 2
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 14, Issue 18, 07 May 2009
Rapid communications
First sequence-confirmed case of infection with the new influenza A(H1N1) strain in Germany
  1. Institute of Medical Microbiology and Hygiene, University of Regensburg Medical Centre, Regensburg, Germany
  2. present address: Microbiology Laboratory Mattes and Kochanowski, Neuötting, Germany
  3. Department of Internal Medicine, District Hospital, Mallersdorf, Germany
  4. Department of Internal Medicine 1, University of Regensburg Medical Centre, Regensburg, Germany

Citation style for this article: Melzl H, Wenzel JJ, Kochanowski B, Feierabend K, Kreuzpaintner B, Kreuzpaintner E, Rohrhofer A, Schreder-Meindl S, Wollner H, Salzberger B, Reischl U, Jilg W, Wolf H, Niller HH. First sequence-confirmed case of infection with the new influenza A(H1N1) strain in Germany. Euro Surveill. 2009;14(18):pii=19203. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19203
Date of submission: 03 May 2009

Here, we report on the first sequence-confirmed case of infection with the new influenza A(H1N1) virus in Germany. Two direct contacts of the patient were laboratory-confirmed as cases and demonstrate a chain of direct human-to-human transmission.
A patient in his 30s was admitted to the department of internal medicine of a district hospital in southern Germany, on 24 April 2009 with influenza symptoms. Two days earlier, he had returned from a vacation in Mexico. He presented with fever up to 40° C, cough and dyspnoea. Headache and myalgia were not present. In addition, this patient had an unrelated, previously undiagnosed chronic disease. He was isolated on the morning of 27 April, and fever and dyspnoea resolved during that day. Since the evening of that day, he has been treated with oseltamivir. Because of his underlying medical condition he was transferred to the University Medical Centre on 28 April, where he has been in stable condition until present, with no further clinical signs of influenza.

Laboratory analysis

On 27 April 2009, the Laboratory of Medical Microbiology and Hygiene at the University of Regensburg Medical Center received a nose and throat swab of the patient for influenza PCR, because an infection with the new influenza A(H1N1) strain was suspected [1,2].

TaqMan-PCR for an 86 bp fragment of the M1 matrix protein gene was performed on the same day and was negative for influenza B, but weakly positive for influenza A (102-103 copies from 1 ml of swab extraction buffer). The two involved hospitals and health authorities were informed immediately. The primers used (set A, see Table) were part of an in house TaqMan-PCR system designed for conventional influenza A strains.

Sequencing of this PCR product on 28 April showed that 45 bp excluding the primers were identical to the California 04/2009 H1N1 isolate from the current outbreak (GenBank entry FJ966085.1). The 45 bp sequence differed in three nucleotide positions from conventional human influenza A strains, two of them within the TaqMan probe region. This was considered a strong indication for infection with the new virus.


Table. Oligonucleotide primers used for amplification and sequencing

 

A larger 600 bp PCR fragment of the matrix protein gene was sequenced on the same evening, using primer set B (see Table). In a BLAST search it was 100% identical over a stretch of 597 nucleotides with the above mentioned California isolate, but differed in at least 5% from annotated human influenza A(H1N1) strains. Conventional porcine influenza H3N2, but also H1N1 strains, were generally more closely related to our sequence than human strains.
Therefore, we considered this isolate as the first proven case of the new influenza A(H1N1) in Germany. Health authorities and physicians were immediately informed. The 597 nucleotide sequence was submitted to GenBank on the same day (FJ970928*).

In parallel, a 1,446 bp fragment of the haemagglutinin gene was amplified and sequenced using primer set C (see Table), and submitted to GenBank (FJ974021) on 30 April. This sequence was identical to two California strains (GenBank FJ969511 and FJ966952) isolated in the current worldwide outbreak, with the exception of only one nucleotide mismatch. In addition a 1,109 bp sequence of the neuraminidase gene of our first isolate has meanwhile been deposited in GenBank (FJ984953) and in the database of the Global Initiative on Sharing Avian Influenza Data (GISAID). It had 100% similarity with the Texas/04 and Texas/05 isolates (FJ981614 and FJ966969).

Contact testing

In the presumed incubation time, the index patient had several contacts of varying closeness and duration before his admission to hospital. Contact tracing and testing through the public health authorities was started immediately. Detailed data on the contacts of the index patient before entering the hospital will be reported by the public health authorities.

Before the patient was isolated on the morning of 27 April under suspicion of new influenza, he had an estimated 19 close contacts among staff at the district hospital and one patient who stayed in the same twin room as the index case in the district hospital. 

One of the nurses who had close contact with him has so far tested positive for the new influenza A (H1N1), and had influenza symptoms for a period of two days on 26-27 April. This case received oseltamivir treatment and stayed isolated at home until 5 May when she had tested negative for the new influenza A(H1N1) strain. 
All other contacts among the district hospital staff and additional hospital staff who had not had contact with the index patient (a total of 32 people) were tested one or two times and have remained PCR-negative and healthy as of 7 May.
All 32 were tested and offered oseltamivir prophylaxis, but only a minority accepted the treatment. Contacts among the staff at the University Medical Centre remained healthy and were not tested, because the isolation care of the patient was continued without interruption from the beginning.

A sputum sample of the patient sharing the room with the index case was found positive on 29 April in an influenza A-specific TaqMan-PCR assay (set A, see Table). A second TaqMan-PCR assay, specific for the new influenza A(H1N1) strain (primer set D, see Table), was found positive on the same day. The patient was isolated and treated with oseltamivir in the afternoon of 29 April, and health authorities were informed. He suffered only minor influenza-like symptoms.
Both this and the index patient have since tested negative for the new influenza A(H1N1) strain three times and have been released from isolation. Due to additional chronic diseases unrelated to influenza, however, they have not been released from the hospital yet.

Acknowledgments:
Both first authors, H. Melzl and J. Wenzel (in alphabetical order) contributed equally to this work. We are deeply grateful to L-S. Bachmann-Dietl, M. Pregler and H. Körber from the Regensburg, B Biermaier* from the Straubing, and P. Ziegler from the Landshut public health authorities, the Bayerische Landesamt für Gesundheit und Lebensmittelsicherheit (LGL), the Bavarian Ministry for the Environment and Health, and the Robert Koch-Institute (RKI), Berlin for their excellent cooperation. Sequencing primer set C was rapidly provided by Metabion, Martinsried, Germany. TaqMan-PCR system D, specific for the new influenza A(H1N1) strain was designed by M. Panning, Freiburg, and C. Drosten, Bonn, and kindly provided by O. Landt, Tib-MolBiol, Berlin.


* Authors’ correction:
On 8 May 2009, the following changes were made in this article: B Kochanowski was added to the author list. B Biermaier from the Straubing public health authorities was added to the Acknowledgements section. The GenBank entry "JF970928" was corrected to read "FJ970928" at the end of the fifth paragraph.


References:

  1. Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1) virus infection --- Mexico, March--April 2009. MMWR Morb Mortal Wkly Rep. MMRW 2009; 58(Dispatch):1-3. Available from: www.cdc.gov/mmwr/preview/mmwrhtml/mm58d0430a2.htm
  2. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children---Southern California, March--April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(15):400-2. Available from: www.cdc.gov/mmwr/preview/mmwrhtml/mm5815a5.htm
  3. Schweiger B, Biere B. TaqMan real-time PCR zur Detektion von porcinen Influenza A/H1N1-Viren. [TaqMan real-time PCR for the detection of porcine influenza A/H1N1 viruses. [In German]. Berlin: Robert Koch-Institute; 2009 May 3. Available from: http://www.rki.de/cln_100/nn_200120/DE/Content/InfAZ/I/Influenza/IPV/Schweinegrippe__PCR,templateId=raw,property=publicationFile.pdf/Schweinegrippe_PCR.pdf


Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.